Saccharomyces cerevisiae strain 905 reduces the translocation of Salmonella enterica serotype typhimurium and stimulates the immune system in gnotobiotic and conventional mice

Journal of Medical Microbiology

Volumn 56, Issue 3, 2007, Pages 352-359

  Martins, Flaviano S ^a,b   Rodrigues, Ana Cristina P ^c   Tiago, Fabiana C P ^a   Penna, Francisco J ^a   Rosa, Carlos A ^a   Arantes, Rosa M E ^a   Mardi, Regina M D ^a   Neves, Maria J ^b   Nicoli, Jacques R ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b CENTRO DE DESENVOLVIMENTO DA TECNOLOGIA NUCLEAR   (Brazil)

^c Universidade Jose do Rosario Vellano   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PROBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL TRANSLOCATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL INFECTION; GNOTOBIOTICS; GRAM NEGATIVE INFECTION; HISTOLOGY; IMMUNE SYSTEM; IMMUNOGLOBULIN PRODUCTION; KUPFFER CELL; LIVER; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; PEYER PATCH; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; SALMONELLA ENTERICA; SALMONELLA TYPHIMURIUM; SEROTYPE; STRAIN DIFFERENCE; TRAVELLER DIARRHEA;

ANIMALS; ANTIBODIES, BACTERIAL; BACTEREMIA; BACTERIAL TRANSLOCATION; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FECES; GERM-FREE LIFE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULIN M; KUPFFER CELLS; LIVER; LYMPH NODES; MICE; PEYER'S PATCHES; SACCHAROMYCES CEREVISIAE; SALMONELLA INFECTIONS, ANIMAL; SALMONELLA TYPHIMURIUM; SPLEEN;

EID: 33847685870     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.46525-0     Document Type: Article

References (48)

1. Bartlett, J. G. (1992). Antibiotic-associated diarrhea. Clin Infect Dis 15, 573-581.
2. Berg, R. D. (1995). Bacterial translocation from the gastrointestinal tract. Trends Microbiol 3, 149-154.
3. Berg, R. D. (1996). The indigenous gastrointestinal microflora. Trends Microbiol 4, 430-435.
4. Born, P., Lersch, C., Zimmerhackl, B. & Claassen, M. (1993). The Saccharomyces boulardii therapy of HIV-associated diarrhea. Dtsch Med Wochenschr 118, 765.
5. Brandão, R. L., Castro, I. M., Bambirra, E. A., Amaral, S. C., Fietto, L. G., Tropia, M. J. M., Neves, M. J., Dos Santos, R. G., Gomes, N. C. M. & Nicoli, J. R. (1998). Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiae. Appl Environ Microbiol 64, 564-568.
6. Buts, J. P., Bernasconi, P., Vaerman, J. P. & Dive, C. (1990). Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci 35, 251-256.
7. Castagliuolo, I., Riegler, M. F., Valenick, L., Lamont, J. T. & Pothoulakis, C. (1999). Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 67, 302-307.
8. Chiva, M., Soriano, G., Rochat, I., Peralta, C., Rochat, F., Llovet, T., Mirelis, B., Schiffrin, E. J., Guarner, C. & Balanzo, J. (2002). Effect of Lactobacillus johnsonii La1 and antioxidants on intestinal flora and bacterial translocation in rats with experimental cirrhosis. J Hepatol 37, 456-462.
9. Ciriello, C. J. & Lachance, M. A. (2001). YEASTCOMPARE. University of Western Ontario, London, ON, Canada.
10. Czerucka, D. & Rampal, P. (2002). Experimental effects of Saccharomyces boulardii on diarrheal pathogens. Microbes Infect 4, 733-739.
11. Czerucka, D., Roux, I. & Rampal, P. (1994). Saccharomyces boulardii inhibits secretagogue-mediated adenosine 3′,5′-cyclic monophosphate induction in intestinal cells. Gastroenterology 106, 65-72.
12. Czerucka, D., Dahan, S., Mograbi, B., Rossi, B. & Rampal, P. (2000). Saccharomyces boulardii preserves the barrier function and modulates the transduction pathway induced in enteropathogenic Escherichia coil-infected T84 cells. Infect Immun 68, 5998-6004.
13. Dahan, S., Dalmasso, G., Imbert, V., Peyron, J.-F., Rampal, P. & Czerucka, D. (2003). Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells. Infect Immun 71, 766-773.
14. Elmer, G. W., McFarland, L. V., Surawicz, C. M., Danko, L. & Greenberg, R. N. (1999). Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol Ther 13, 1663-1668.
15. Fietto, J. L. R., Araujo, R. S., Valadão, F. N., Fietto, L. G., Brandão, R. L., Neves, M. J., Gomes, C. O., Nicoli, J. R. & Castro, I. M. (2004). Molecular and physiological comparisons between Saccharomyces cerevisiae and Saccharomyces boulardii. Can J Microbiol 50, 615-621.
16. Food and Agriculture Organization of the United Nations & World Health Organization (2002). Guidelines for the Evaluation of Probiotics in Food, Food and Agriculture Organization of the United Nations and World Health Organization Working Group Report, London, Ontario, Canada, April 30-May 1 2002.
17. Gregory, S. H., Sagnimeni, A. J. & Wing, E. J. (1996). Bacteria in the bloodstream are trapped in the liver and killed by immigrating neutrophils. J Immunol 157, 2514-2520.
18. Gedek, B. R. (1999). Adherence of Escherichia coli serogroup O157 and the Salmonella typhimurium mutant DT 104 to the surface of Saccharomyces boulardii. Mycoses 42, 261-264.
19. Gun, F., Salman, T., Gurler, N. & Olgac, V. (2005). Effect of probiotic supplementation on bacterial translocation in thermal injury. Surg Today 35, 760-764.
20. Hajishengallis, G., Nikolova, E. & Russel, M. W. (1992). Inhibition of Streptococcus mutans adherence to saliva-coated hydroxyapatite by human secretory immunoglobulin A antibodies to the cell surface protein antigen I/II: reversal by IgA 1 protease cleavage. Infect Immun 60, 5057-5064.
21. Hamuro, J., Akiyama, Y., Iguchi, Y., Isawa, M. & Matsuo, T. (1982). Distinct roles of serum factors induced by a T cell specific immune adjuvant lentinan in cellular immune responses. Int J Immunopharmacol 4, 268.
22. Herek, O., Kara, I. G. & Kaleli, I. (2004). Effects of antibiotics and Saccharomyces boulardii on bacterial translocation in burn injury. Surg Today 34, 256-260.
23. Hirakata, Y., Tomono, K., Tateda, K., Matsumoto, T., Furuya, N., Shimoguchi, K., Kaku, M. & Yamaguchi, K. (1991). Role of bacterial association with Küpffer cells in occurrence of endogenous systemic bacteremia. Infect Immun 59, 289-294.
24. Jahn, H. U., Ullrich, R., Schneider, T., Liehr, R. M., Schieferdecker, H. L., Holst, H. & Zeitz, M. (1996). Immunological and trophical effects of Saccharomyces boulardii on the small intestine in healthy human volunteers. Digestion 57, 95-104.
25. Jones, B. D. & Falkow, S. (1996). Salmonellosis: host immune responses and bacterial virulence determinants. Annu Rev Immunol 14, 533-561.
26. Kovacs, D. J. & Berk, T. (2000). Recurrent Clostridium difficile-associated diarrhea and colitis treated with Saccharomyces cerevisiae (baker's yeast) in combination with antibiotic therapy: a case report. J Am Board Farm Pract 13, 138-140.
27. Kumura, H., Tanoue, Y., Tsukahara, M., Tanaka, T. & Shimazaki, K. (2004). Screening of dairy yeast strains for probiotic applications. J Dairy Sci 87, 4050-4056.
28. Martins, F. S., Nardi, R. M. D., Arantes, R. M. E., Rosa, C. A., Neves, M. J. & Nicoli, J. R. (2005). Screening of yeast as probiotic based on capacities to colonize the gastrointestinal tract and to protect against enteropathogen challenge in mice. J Gen Appl Microbiol 51, 83-92.
29. McFarland, L. V. & Bernasconi, P. (1993). Saccharomyces boulardii: a review of an innovative biotherapeutic agent. Microb Ecol Health Dis 6, 157-171.
30. McFarland, L. V., Surawicz, C. M., Greenberg, R. N., Elmer, G. W., Mover, K. A., Melcher, S. A., Bowen, K. E. & Cox, J. L. (1995). Prevention of β-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 90, 439-448.
31. Moreau, M. C., Raibaud, P. & Muller, M. C. (1982). Relation entre le développement du système immunitaire intestinal à IgA et l'établissement de la flore microbienne dans le tube digestif de souris holoxênique. Ann Inst Pasteur Immunol 133B, 29-39.
32. Moura, L. N., Neumann, E., Vieira, L. Q. & Nicoli, J. R. (2001). Protection by Lactobacillus acidophilus UFV-H2B20 against experimental oral infection with Salmonella enterica subsp. enterica ser. Typhimurium in gnotobiotic and conventional mice. Br J Microbiol 32, 66-69.
33. National Research Council (1996). Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press.
34. 20 stimulates the phagocytic system of germ-free mice. Br J Med Biol Res 31, 1565-1573.
35. Neves, M. J., Etchebehere, L., Brandão, R. L., Castro, I. M., Lima, M. E. & Nicoli, J. R. (2002). Partial characterization of cholera toxin binding on membranes of Saccharomyces boulardii. Microecol Ther 29, 185-190.
36. Patchen, M. & McVittie, T. (1982). Effects of a soluble glucan on hemopoietic stem cell proliferation. Int J Immunopharmacol 4, 273.
37. Pleasants, J. R. (1974). Gnotobiotics. In Handbook of Laboratory Animal Science, p. 119-174. Edited by E. C. Melby Jr & N. H. Altmann. Cleveland: CRC Press.
38. Peret, L. A., Penna, F. J., Bambirra, E. A. & Nicoli, J. R. (1998). Dose effect of oral Saccharomyces boulardii treatments on morbidity and mortality in immunosuppressed mice. J Med Microbiol 47, 111-116.
39. Pothoulakis, C., Kelly, C. P., Joshi, M. A., Gao, N., O'Keane, C. J., Castagliuolo, I. & Lamont, J. T. (1993). Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 104, 1108-1115.
40. Qamar, A., Aboudola, S., Warny, M., Michetti, P., Pothoulakis, C., Lament, J. T. & Kelly, C. P. (2001). Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 69, 2762-2765.
41. Rodrigues, A. C., Mardi, R. M., Bambirra, E. A., Vieira, E. C. & Nicoli, J. R. (1996). Effect of Saccharomyces boulardii against experimental oral infection with Salmonella typhimurium and Shigella flexneri in conventional and gnotobiotic mice. J Appl Bacteriol 81, 251-256.
42. Rodrigues, A. C., Cara, D. C., Fretez, S. H. G. G., Cunha, F. Q., Vieira, E. C., Nicoli, J. R. & Vieira, L. Q. (2000). Saccharomyces boulardii stimulates sIgA production and the phagocytic system of gnotobiotic mice. J Appl Microbiol 89, 404-414.
43. Saba, T. M. (1970). Physiology and physiopathology of the reticuloendothelial system. Arch Intern Med 126, 1031-1052.
44. Scarpignato, C. & Rampal, P. (1995). Prevention and treatment of traveler's diarrhea: a clinical pharmacological approach. Chemotherapy 41, 48-81.
45. Silva, A. M., Barbosa, F. H. F., Duarte, R., Vieira, L. Q., Arantes, R. M. E.& Nicoli, J. R. (2004). Effect of Bifidobacterium longum ingestion on experimental salmonellosis in mice. J Appl Microbiol 97, 29-37.
46. Surawicz, C. M. (2003). Probiotics, antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in humans. Best Pract Res Clin Gastroenterol 17, 775-783.
47. Surawicz, C. M., McFarland, L. V., Greenberg, R. N., Rubin, M., Fekety, R., Mulligan, M. E., Garcia, R. J., Brandmarker, S., Bowen, K. & other authors (2000). The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 31, 1012-1017.
48. Van der Aa Kühle, A., Skovgaard, K. & Jespersen, L. (2005). In vitro screening of probiotic properties of Saccharomyces cerevisiae var. boulardii and food-borne Saccharomyces cerevisiae strains. Int J Food Microbiol 101, 29-39.